Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11489-11497

  Gheybi, Elaheh ^a,b   Amani, Jafar ^a   Salmanian, Ali Hatef ^c   Mashayekhi, Farhad ^b   Khodi, Samaneh ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF GUILAN   (Iran)

^c NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

Author keywords

Breast cancer; MUC1 HER2; Recombinant chimeric antigen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MUC1 PROTEIN, HUMAN; MUCIN 1;

ADULT; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BREAST; BREAST NEOPLASMS; CASE CONTROL STUDY; COMPARATIVE STUDY; DIAGNOSTIC USE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOUSE; NUDE MOUSE; WESTERN BLOTTING; YOUNG ADULT;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MUCIN-1; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 84927798991     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2483-y     Document Type: Article

References (33)

1. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol. 2011;12(5):477–88. doi:10.1016/S1470-2045(11)70076-6.
2. Castano Z, Tracy K, McAllister SS. The tumor macroenvironment and systemic regulation of breast cancer progression. Int J Dev Biol. 2011;55(7–9):889–97. doi:10.1387/ijdb.113366zc.
3. Moelans CB, de Weger RA, Van der Wall E, van Diest PJ. Current technologies for HER2 testing in breast cancer. Crit Rev Oncol/Hematol. 2011;80(3):380–92. doi:10.1016/j.critrevonc.2010.12.005.
4. Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn. 2009;9(5):455–67. doi:10.1586/erm.09.25.
5. Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol. 2004;1(4):247–55.
6. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res BCR. 2004;6(3):109–18. doi:10.1186/bcr777.
7. Mazor Y, Keydar I, Benhar I. Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificity. Mol Immunol. 2005;42(1):55–69. doi:10.1016/j.molimm.2004.07.013.
8. Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5(4):865–74.
9. Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res BCR. 2006;8(3):R27. doi:10.1186/bcr1505.
10. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010;70(4):1306–13. doi:10.1158/0008-5472.CAN-09-2893.
11. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer. 2011;10(1):15. doi:10.1186/1476-4598-10-15.
12. Mushenkova N, Moiseeva E, Chaadaeva A, Den Otter W, Svirshchevskaya E. Antitumor effect of double immunization of mice with mucin 1 and its coding DNA. Anticancer Res. 2005;25(6B):3893–8.
13. Albrecht H, Carraway 3rd KL. MUC1 and MUC4: switching the emphasis from large to small. Cancer Biother Radiopharm. 2011;26(3):261–71. doi:10.1089/cbr.2011.1017.
14. Tang Y, Wang L, Zhang P, Wei H, Gao R, Liu X, et al. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol CVI. 2010;17(12):1903–8. doi:10.1128/CVI.00142-10.
15. Daniele L, Sapino A. Anti-HER2 treatment and breast cancer: state of the art, recent patents, and new strategies. Recent Patents Anti Cancer Drug Discov. 2009;4(1):9–18.
16. Mohanty K, Saha A, Pal S, Mallick P, Chatterjee SK, Foon KA, et al. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu. Breast Cancer Res Treat. 2007;104(1):1–11. doi:10.1007/s10549-006-9391-9.
17. Goodell V, Waisman J, Salazar LG, de la Rosa C, Link J, Coveler AL, et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther. 2008;7(3):449–54. doi:10.1158/1535-7163.MCT-07-0386.
18. Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059–70. doi:10.1007/s10875-012-9689-9.
19. Amani J, Salmanian AH, Rafati S, Mousavi SL. Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7. Vaccine. 2010;28(42):6923–9. doi:10.1016/j.vaccine.2010.07.061.
20. Schunk MK, Macallum GE. Applications and optimization of immunization procedures. ILAR J/Natl Res Counc Inst Lab Anim Resour. 2005;46(3):241–57.
21. Assarehzadegan MA, Sankian M, Jabbari F, Tehrani M, Varasteh A. Expression of the recombinant major allergen of Salsola kali pollen (Sal k 1) and comparison with its low-immunoglobulin E-binding mutant. Allergol Int Off J Jpn Soc Allergol. 2010;59(2):213–22. doi:10.2332/allergolint.09-OA-0155.
22. Dominguez WG, Nardi H, Montero H, Vincent E, Corte MM, Balogh GA. HER2/neu protein expression and fine needle breast aspiration from Argentinean patients with non-palpable breast lesions. Exp Ther Med. 2010;1(4):597–602. doi:10.3892/etm_00000094.
23. Brocke C, Kunz H. Synthesis of tumor-associated glycopeptide antigens. Bioorg Med Chem. 2002;10(10):3085–112.
24. Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(14):4733–41. doi:10.1158/1078-0432.CCR-08-3307.
25. Mirabelli P, Incoronato M. Usefulness of traditional serum biomarkers for management of breast cancer patients. BioMed Res Int. 2013;2013:685641. doi:10.1155/2013/685641.
26. Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res Off J Am Assoc Cancer Res. 2000;6(6):2363–70.
27. Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat. 2003;81(3):195–207. doi:10.1023/A:1026110417294.
28. Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila). 2012;5(8):1036–43. doi:10.1158/1940-6207.CAPR-11-0558.
29. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med. 2000;161(2 Pt 1):589–94. doi:10.1164/ajrccm.161.2.9905028.
30. Isla Larrain M, Demichelis S, Crespo M, Lacunza E, Barbera A, Creton A, et al. Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1). J Exp Clin Cancer Res CR. 2009;28:121. doi:10.1186/1756-9966-28-121.
31. Pichinuk E, Benhar I, Jacobi O, Chalik M, Weiss L, Ziv R, et al. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells. Cancer Res. 2012;72(13):3324–36. doi:10.1158/0008-5472.CAN-12-0067.
32. Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, et al. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab—a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer. 2012;107(6):956–60. doi:10.1038/bjc.2012.353.
33. Ma L, Yang H, Han X, LI J, Wang F, Zhang C-l, et al. Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer. Chin Med J. 2012;125:4104–10.